|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 672.14 USD | -0.67% |
|
+1.78% | -12.56% |
| 07-16 | Merck gets US FDA nod for first-in-its-class oral cholesterol drug | RE |
| 07-15 | Alnylam Initiates Mid-Stage Study of Mivelsiran in Down Syndrome-Associated Alzheimer's | MT |
Main competitors
| Change | 5-day change | 1-month change | 3-month change | YTD change | 1-year change | 3-year change | 5-year change | 10-year change | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
 | -0.67% | +1.78% | +10.19% | -9.94% | -12.56% | +23.71% | -6.66% | +14.93% | +75.44% | 68.85B | |
| -0.46% | +1.10% | -3.80% | -8.03% | -0.17% | +37.45% | +190.20% | +168.73% | +243.52% | 52.13B | |
| +0.94% | +39.60% | +39.60% | +39.60% | +39.60% | +39.60% | +39.60% | +39.60% | - | 43.46B | |
| -0.58% | +1.05% | +8.62% | -10.78% | -28.98% | -51.98% | -53.78% | -57.20% | +4.79% | 41.24B | |
| -1.74% | -2.68% | +1.86% | +10.95% | +15.59% | +65.81% | -25.95% | -36.92% | -22.48% | 30.41B | |
| -1.04% | -8.79% | +2.99% | +11.96% | +107.26% | +97.35% | -51.01% | -80.11% | - | 24.53B | |
| -0.99% | +1.85% | +12.23% | +20.04% | +17.79% | +72.66% | +81.75% | +46.88% | +33.91% | 23.42B | |
| +3.99% | +3.82% | +22.76% | +1.54% | +21.31% | +4.34% | +196.00% | +6.20% | - | 19.75B | |
| +0.35% | +0.17% | +3.87% | +10.53% | +38.82% | +71.75% | +126.03% | +187.67% | +328.17% | 16.57B | |
| -0.09% | -2.11% | +18.01% | +6.06% | +6.33% | +77.19% | +135.81% | +33.09% | - | 15.95B | |
| +0.11% | +0.63% | -7.32% | +21.74% | +25.77% | +109.44% | +208.63% | +314.94% | +2,750.00% | 11.84B | |
| -0.56% | -0.01% | +5.89% | +7.86% | -0.40% | +4.66% | -32.38% | -25.54% | -36.87% | 11.52B | |
| -1.51% | -3.55% | +2.07% | +26.78% | +42.19% | +136.71% | +184.42% | +457.40% | - | 10.46B | |
| -4.16% | -14.66% | -21.78% | -24.45% | -38.49% | -43.57% | +557.55% | +276.62% | +4,270.58% | 9.96B | |
| +3.33% | +4.87% | +3.52% | -0.32% | -12.67% | -21.08% | -31.80% | -54.57% | -53.32% | 6.28B | |
| -3.10% | +0.10% | +6.19% | +46.15% | +185.12% | +160.11% | +286.33% | -25.45% | - | 5.84B | |
| -13.72% | -16.53% | +9.76% | -25.49% | +7.27% | +9.23% | +249.19% | +244.85% | - | 5.83B | |
| -7.39% | -3.31% | +13.35% | -1.35% | -5.58% | +9.36% | +52.30% | -23.70% | - | 5.64B | |
| -4.52% | -0.66% | +0.04% | -28.01% | -36.47% | -52.43% | -55.40% | -78.82% | - | 5.33B | |
| +6.38% | -3.75% | +6.77% | -30.61% | -28.95% | -42.35% | +137.95% | +111.06% | +115.83% | 5.14B | |
| Average | -1.26% | -2.40% | +6.74% | +3.21% | +17.14% | +35.40% | +109.44% | +75.98% | +700.87% | 20.71B | |
| Weighted average by Cap. | -0.59% | -0.84% | +9.20% | +4.25% | +12.96% | +35.05% | +72.86% | +55.25% | +355.32% |
- Stock Market
- Stocks
- REGN Stock
- Sector Regeneron Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
